The Jackson Laboratory
Research
Gareth Howell PhD, is an Associate Professor and the Diana Davis Spencer Foundation chair for Glaucoma Research at The Jackson Laboratory (JAX). He is a member of the executive committee of the JAX Center for Alzheimer’s and dementia research and a lead principal investigator of MODEL-AD. His research focuses on developing translationally relevant mouse models for neurodegenerative diseases including Alzheimer’s disease, related dementias, and glaucoma. He then uses these models to identify strategies to manipulate inflammatory responses and vascular changes to treat these diseases. Before joining the JAX faculty in 2012, Dr. Howell received a Ph.D. in comparative genomics and bioinformatics at the Wellcome Sanger Institute (Cambridge, UK) where he was part of the team that sequenced the first human genome. He was a postdoctoral fellow at JAX and The University of Sheffield, UK.

Moderator of 1 Session

Session Type
SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
04:15 PM - 06:00 PM
Room
ONSITE: 131-132

Presenter of 1 Presentation

LOAD2: A NOVEL MOUSE MODEL FOR INVESTIGATING INTERACTIONS BETWEEN GENETIC AND ENVIRONMENTAL RISK FACTORS FOR LATE-ONSET ALZHEIMER'S DISEASE

Session Type
SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
04:15 PM - 06:00 PM
Room
ONSITE: 131-132
Lecture Time
04:15 PM - 04:30 PM

Abstract

Aims

MODEL-AD (Model Organism Development and Evaluation for Late-onset AD) is developing and characterizing novel mouse models that aim to better phenocopy human LOAD for preclinical testing.

Methods

APOE4 and Trem2*R47H were incorporated into C57BL/6J (B6) mice to produce LOAD1. A humanized amyloid-beta (Aβ) allele was added to LOAD1 mice to form the LOAD2 strain. Female and male LOAD1 and LOAD2 mice on control diet (CD) or high fat diet (HFD) are being assessed for behavior, cognition, in vivo imaging of brain perfusion and metabolism, fluid biomarkers, neuropathology, transcriptomics, metabolomics, proteomics, dendritic spine density and long-term potentiation (LTP) from 4-24 months of age (mos).

Results

Compared to other groups, at 12 mos, LOAD2 mice on HFD showed elevated levels of insoluble Aβ42. LOAD2 mice on HFD also showed reduced density of cortical neurons. These brain changes correlated with elevated levels of TNFa and IL10 in the plasma and neurofilament light chain in cerebral spinal fluid. At 24 mos, accumulation of human APP was observed in cortical neurons of LOAD2 mice on CD suggesting that Aβ processing and clearance may be perturbed. Both LTP and dendritic spine density were reduced from 4 mos in LOAD2 mice on CD similar to previous reports for APOE4 mice. However, these changes were not correlated with deficits in hippocampal spatial working memory.

Conclusions

The combination of aging, genetic risk (APOE4, Trem2*R47H, humanized Aβ) with HFD as an environmental risk induced age-dependent LOAD-relevant phenotypes making LOAD2 mice a useful tool for mechanistic studies and therapeutic testing.

Hide